Medtronic (NYSE:MDT) could avoid a major headache if the courts continue to allow the doctrine of preemption in product liability lawsuits filed over its InFuse bone-growth protein, according to Fish & Richardson principal José Sierra.
Resorbable bone materials
A California state court ruled out a series of motions seeking to dismiss a lawsuit filed over bone proteins made by Stryker and Medtronic, ruling that federal law does not preempt the case from going forward.
Startup medical device company Tissue Regeneration Systems raised $4.6 million in an equity financing round led by Venture Investors, CEO Jim Fitzsimmons told MassDevice.com.
The round was also supported by the Wisconsin Alumni Research Foundation, the University of Michigan and the state of Wisconsin, Fitzsimmons told us.